{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T19:03:57Z","timestamp":1767035037562},"reference-count":18,"publisher":"American Society of Consultant Pharmacists","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2007,10,1]]},"DOI":"10.4140\/tcp.n.2007.847","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T02:10:14Z","timestamp":1294884614000},"page":"847-854","source":"Crossref","is-referenced-by-count":2,"title":["Disparities in the Prevalence of Medication Therapy for Hyperlipidemia in the Elderly"],"prefix":"10.4140","volume":"22","author":[{"given":"Mark A.","family":"Stratton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea H.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald L.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elgene W.","family":"Jacobs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie J.","family":"Skaggs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2009,7,2]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(98)10279-9","article-title":"Lifetime risk of developing coronary artery disease","volume":"353","author":"D Lloyd-Jones","year":"1999","journal-title":"Lancet"},{"key":"2","first-page":"1383","article-title":"Randomized trial of cholesterol lowering in 444 patients with coronary heart disease","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"J Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"F Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS","volume":"279","author":"J Downs","year":"1998","journal-title":"JAMA"},{"key":"6","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1161\/01.CIR.96.12.4211","article-title":"Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris","volume":"96","year":"1997","journal-title":"Circulation"},{"key":"8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/0003-4819-129-9-199811010-00002","article-title":"Effects of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) trial","volume":"129","author":"S Lewis","year":"1998","journal-title":"Ann Intern Med"},{"key":"9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.7326\/0003-4819-134-10-200105150-00007","article-title":"Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial","volume":"134","author":"D Hunt","year":"2001","journal-title":"Ann Intern Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinte.154.5.529","article-title":"Cholesterol lowering in the elderly. Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study","volume":"154","author":"J LaRosa","year":"1994","journal-title":"Arch Intern Med"},{"key":"11","first-page":"793","article-title":"Long-term effects of pravastatin on serum lipid levels in elderly patients with hyperlipidemia","volume":"16","author":"S Morimoto","year":"1994","journal-title":"Clin Ther"},{"key":"12","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial","volume":"360","author":"J Shepherd","year":"2002","journal-title":"Lancet"},{"key":"13","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9149(99)80474-3","article-title":"Range of serum cholesterol values in the population developing coronary artery disease","volume":"76","author":"W Kannel","year":"1995","journal-title":"Am J Cardiol"},{"key":"14","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1001\/archinte.158.16.1761","article-title":"Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study","volume":"158","author":"R Lemaitre","year":"1998","journal-title":"Arch Intern Med"},{"key":"15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/heart.88.1.25","article-title":"Low prevalence of lipid lowering drug use in older men with established coronary heart disease","volume":"88","author":"P Whincup","year":"2002","journal-title":"Heart"},{"key":"16","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1001\/jama.291.15.1864","article-title":"Lipid-lowering therapy with statins in high-risk elderly patients","volume":"291","author":"D Ko","year":"2004","journal-title":"JAMA"},{"key":"17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"NCEP Report. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines","volume":"110","author":"S Grundy","year":"2004","journal-title":"Circulation"},{"key":"18","first-page":"14","article-title":"Deaths: leading causes for 2001","volume":"52","author":"R Anderson","year":"2003","journal-title":"National Vital Statistics Report"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T18:17:26Z","timestamp":1497896246000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2007\/00000022\/00000010\/art00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,1]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10,1]]}},"alternative-id":["P60L8565T82851P5"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2007.847","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10,1]]}}}